Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

PMID:
30404863
2.

Copenhagen Prospective Personalized Oncology (CoPPO) - Clinical utility of using molecular profiling to select patients to phase 1 trials.

Tuxen IV, Rohrberg KS, Østrup O, Ahlborn LB, Schmidt AY, Spanggaard I, Hasselby JP, Santoni-Rugiu E, Yde CW, Mau-Soerensen M, Nielsen FC, Lassen U.

Clin Cancer Res. 2018 Oct 1. pii: clincanres.1780.2018. doi: 10.1158/1078-0432.CCR-18-1780. [Epub ahead of print]

PMID:
30274980
3.

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors.

Ahlborn LB, Tuxen IV, Mouliere F, Kinalis S, Schmidt AY, Rohrberg KS, Santoni-Rugiu E, Nielsen FC, Lassen U, Yde CW, Oestrup O, Mau-Sorensen M.

Oncotarget. 2018 Aug 24;9(66):32570-32579. doi: 10.18632/oncotarget.25948. eCollection 2018 Aug 24.

4.

Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols.

Ahlborn LB, Madsen M, Jonson L, Nielsen FC, Lassen U, Yde CW, Mau-Sorensen M.

Clin Lab. 2017 Oct 1;63(10):1755-1759. doi: 10.7754/Clin.Lab.2017.170516.

PMID:
29035458
5.

Next-Generation Sequencing-Based Detection of Germline Copy Number Variations in BRCA1/BRCA2: Validation of a One-Step Diagnostic Workflow.

Schmidt AY, Hansen TVO, Ahlborn LB, Jønson L, Yde CW, Nielsen FC.

J Mol Diagn. 2017 Nov;19(6):809-816. doi: 10.1016/j.jmoldx.2017.07.003. Epub 2017 Aug 17.

6.

Detection of copy number alterations in cell-free tumor DNA from plasma.

Østrup O, Ahlborn LB, Lassen U, Mau-Sørensen M, Nielsen FC.

BBA Clin. 2017 Apr 4;7:120-126. doi: 10.1016/j.bbacli.2017.03.006. eCollection 2017 Jun.

7.

Validation study of HPV DNA detection from stained FNA smears by polymerase chain reaction: Improving the diagnostic workup of patients with a tumor on the neck.

Channir HI, Grønhøj Larsen C, Ahlborn LB, van Overeem Hansen T, Gerds TA, Charabi BW, Vainer B, von Buchwald C, Lajer CB, Kiss K.

Cancer Cytopathol. 2016 Nov;124(11):820-827. doi: 10.1002/cncy.21753. Epub 2016 Jul 12.

8.

Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.

Jønson L, Ahlborn LB, Steffensen AY, Djursby M, Ejlertsen B, Timshel S, Nielsen FC, Gerdes AM, Hansen TV.

Breast Cancer Res Treat. 2016 Jan;155(2):215-22. doi: 10.1007/s10549-015-3674-y. Epub 2016 Jan 6.

PMID:
26740214
9.

Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic.

Ahlborn LB, Dandanell M, Steffensen AY, Jønson L, Nielsen FC, Hansen TV.

Breast Cancer Res Treat. 2015 Apr;150(2):289-98. doi: 10.1007/s10549-015-3313-7. Epub 2015 Feb 28.

10.

Identification of a breast cancer family double heterozygote for RAD51C and BRCA2 gene mutations.

Ahlborn LB, Steffensen AY, Jønson L, Djursby M, Nielsen FC, Gerdes AM, Hansen TV.

Fam Cancer. 2015 Mar;14(1):129-33. doi: 10.1007/s10689-014-9747-y.

PMID:
25154786

Supplemental Content

Loading ...
Support Center